Cargando…

C-reactive protein and cancer risk: a pan-cancer study of prospective cohort and Mendelian randomization analysis

BACKGROUND: Although observational studies have reported associations between serum C-reactive protein (CRP) concentration and risks of lung, breast, and colorectal cancer, inconsistent or absent evidences were showed for other cancers. We conducted a pan-cancer analysis to comprehensively assess th...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Meng, Ma, Zhimin, Zhang, Xu, Hang, Dong, Yin, Rong, Feng, Jifeng, Xu, Lin, Shen, Hongbing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9484145/
https://www.ncbi.nlm.nih.gov/pubmed/36117174
http://dx.doi.org/10.1186/s12916-022-02506-x
_version_ 1784791822579531776
author Zhu, Meng
Ma, Zhimin
Zhang, Xu
Hang, Dong
Yin, Rong
Feng, Jifeng
Xu, Lin
Shen, Hongbing
author_facet Zhu, Meng
Ma, Zhimin
Zhang, Xu
Hang, Dong
Yin, Rong
Feng, Jifeng
Xu, Lin
Shen, Hongbing
author_sort Zhu, Meng
collection PubMed
description BACKGROUND: Although observational studies have reported associations between serum C-reactive protein (CRP) concentration and risks of lung, breast, and colorectal cancer, inconsistent or absent evidences were showed for other cancers. We conducted a pan-cancer analysis to comprehensively assess the role of CRP, including linearity and non-linearity associations. METHODS: We analyzed 420,964 cancer-free participants from UK Biobank cohort. Multivariable-adjusted Cox proportional hazards model was conducted to evaluate the observed correlation of CRP with overall cancer and 21 site-specific cancer risks. Furthermore, we performed linear and non-linear Mendelian randomization analyses to explore the potential causal relation between them. RESULTS: During a median follow-up period of 7.1 years (interquartile range: 6.3, 7.7), 34,979 incident cancer cases were observed. Observational analyses showed higher CRP concentration was associated with increased risk of overall cancer (hazard ratio (HR) = 1.02, 95% CI: 1.01, 1.02 per 1mg/L increase, P < 0.001). There was a non-linear association between CRP and overall cancer risk with inflection point at 3mg/L (false-discovery rate adjust (FDR-adjusted) P(overall) < 0.001 and FDR-adjusted P(non-linear) < 0.001). For site-specific cancer, we observed positive linear associations for cancers of esophagus and stomach (FDR-adjusted P(overall) < 0.050 and FDR-adjusted P(non-linear) > 0.050). In addition, we also observed three different patterns of non-linear associations, including “fast-to-low increase” (head and neck, colorectal, liver, lung, kidney cancer, and non-Hodgkin lymphoma), “increase-to-decrease” (breast cancer), and “decrease-to-platform” (chronic lymphocytic leukemia). Furthermore, the inflection points of non-linear association patterns were consistently at around 3mg/L. By contrast, there was no evidence for linear or non-linear associations between genetically predicted CRP and risks of overall cancer or site-specific cancers. CONCLUSIONS: Our results indicated that CRP was a potential biomarker to assess risks of overall cancer and 12 site-specific cancers, while no association were observed for genetically-predicted CRP and cancer risks. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12916-022-02506-x.
format Online
Article
Text
id pubmed-9484145
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-94841452022-09-20 C-reactive protein and cancer risk: a pan-cancer study of prospective cohort and Mendelian randomization analysis Zhu, Meng Ma, Zhimin Zhang, Xu Hang, Dong Yin, Rong Feng, Jifeng Xu, Lin Shen, Hongbing BMC Med Research Article BACKGROUND: Although observational studies have reported associations between serum C-reactive protein (CRP) concentration and risks of lung, breast, and colorectal cancer, inconsistent or absent evidences were showed for other cancers. We conducted a pan-cancer analysis to comprehensively assess the role of CRP, including linearity and non-linearity associations. METHODS: We analyzed 420,964 cancer-free participants from UK Biobank cohort. Multivariable-adjusted Cox proportional hazards model was conducted to evaluate the observed correlation of CRP with overall cancer and 21 site-specific cancer risks. Furthermore, we performed linear and non-linear Mendelian randomization analyses to explore the potential causal relation between them. RESULTS: During a median follow-up period of 7.1 years (interquartile range: 6.3, 7.7), 34,979 incident cancer cases were observed. Observational analyses showed higher CRP concentration was associated with increased risk of overall cancer (hazard ratio (HR) = 1.02, 95% CI: 1.01, 1.02 per 1mg/L increase, P < 0.001). There was a non-linear association between CRP and overall cancer risk with inflection point at 3mg/L (false-discovery rate adjust (FDR-adjusted) P(overall) < 0.001 and FDR-adjusted P(non-linear) < 0.001). For site-specific cancer, we observed positive linear associations for cancers of esophagus and stomach (FDR-adjusted P(overall) < 0.050 and FDR-adjusted P(non-linear) > 0.050). In addition, we also observed three different patterns of non-linear associations, including “fast-to-low increase” (head and neck, colorectal, liver, lung, kidney cancer, and non-Hodgkin lymphoma), “increase-to-decrease” (breast cancer), and “decrease-to-platform” (chronic lymphocytic leukemia). Furthermore, the inflection points of non-linear association patterns were consistently at around 3mg/L. By contrast, there was no evidence for linear or non-linear associations between genetically predicted CRP and risks of overall cancer or site-specific cancers. CONCLUSIONS: Our results indicated that CRP was a potential biomarker to assess risks of overall cancer and 12 site-specific cancers, while no association were observed for genetically-predicted CRP and cancer risks. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12916-022-02506-x. BioMed Central 2022-09-19 /pmc/articles/PMC9484145/ /pubmed/36117174 http://dx.doi.org/10.1186/s12916-022-02506-x Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Zhu, Meng
Ma, Zhimin
Zhang, Xu
Hang, Dong
Yin, Rong
Feng, Jifeng
Xu, Lin
Shen, Hongbing
C-reactive protein and cancer risk: a pan-cancer study of prospective cohort and Mendelian randomization analysis
title C-reactive protein and cancer risk: a pan-cancer study of prospective cohort and Mendelian randomization analysis
title_full C-reactive protein and cancer risk: a pan-cancer study of prospective cohort and Mendelian randomization analysis
title_fullStr C-reactive protein and cancer risk: a pan-cancer study of prospective cohort and Mendelian randomization analysis
title_full_unstemmed C-reactive protein and cancer risk: a pan-cancer study of prospective cohort and Mendelian randomization analysis
title_short C-reactive protein and cancer risk: a pan-cancer study of prospective cohort and Mendelian randomization analysis
title_sort c-reactive protein and cancer risk: a pan-cancer study of prospective cohort and mendelian randomization analysis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9484145/
https://www.ncbi.nlm.nih.gov/pubmed/36117174
http://dx.doi.org/10.1186/s12916-022-02506-x
work_keys_str_mv AT zhumeng creactiveproteinandcancerriskapancancerstudyofprospectivecohortandmendelianrandomizationanalysis
AT mazhimin creactiveproteinandcancerriskapancancerstudyofprospectivecohortandmendelianrandomizationanalysis
AT zhangxu creactiveproteinandcancerriskapancancerstudyofprospectivecohortandmendelianrandomizationanalysis
AT hangdong creactiveproteinandcancerriskapancancerstudyofprospectivecohortandmendelianrandomizationanalysis
AT yinrong creactiveproteinandcancerriskapancancerstudyofprospectivecohortandmendelianrandomizationanalysis
AT fengjifeng creactiveproteinandcancerriskapancancerstudyofprospectivecohortandmendelianrandomizationanalysis
AT xulin creactiveproteinandcancerriskapancancerstudyofprospectivecohortandmendelianrandomizationanalysis
AT shenhongbing creactiveproteinandcancerriskapancancerstudyofprospectivecohortandmendelianrandomizationanalysis